Veillonella和乳酸杆菌是通过代谢交叉喂养健康肠道环境的关键调节因子,影响乳酸和短链脂肪酸(SCFA)水平,这对肠道健康至关重要。这项研究旨在调查Veillonellaratti(V.ratti)和嗜酸乳杆菌(LA)相互作用并减轻小鼠模型中葡聚糖硫酸钠(DSS)诱导的溃疡性结肠炎(UC)。我们通过在改良培养基中共培养来评估它们关于碳源的代谢相互作用。在体外实验中,V.ratti和LA在单一培养和共培养中接种,和活细胞计数,OD600,pH,乳酸,测量葡萄糖和SCFA。对于体内实验,将60只C57BL/6小鼠随机分为5组,并通过口服管饲法(每只小鼠每天1×109CFUmL-1)单独或组合施用拉氏弧菌和LA,持续14天。第七天,向饮用水中加入2.5%DSS诱导结肠炎。通过评估肠道微环境中的肠屏障完整性和肠道炎症来评估这些益生菌对UC的作用。体外结果表明,与LA共培养V.ratti显著增加活细胞数,乳酸生产,和SCFA生产,同时降低培养基中的pH和葡萄糖水平。体内研究结果表明,用拉蒂弧菌进行干预,特别是与洛杉矶的组合,缓解症状,包括减肥,结肠缩短,和组织损伤。这些益生菌通过下调促炎分子减轻肠道炎症,如IL-6,IL-1β,IL-γ,iNOS,和IFN-γ,以及氧化应激标志物,包括MDA和MPO。同时,它们上调了抗炎酶的活性,即,SOD和GSH,并促进了SCFA的生产。V.ratti和LA的联合干预显着增加乙酸,丙酸,丁酸,异丁酸,戊酸,和盲肠内容物中的总SCFA。此外,拉蒂弧菌和LA的干预增加了有益菌的丰度,比如Akkermansia,同时减少有害细菌的丰度,如大肠杆菌志贺氏菌和脱硫弧菌,从而减轻过度炎症。这些发现强调了由拉蒂弧菌和LA之间的相互作用产生的增强的治疗效果。证明了这种联合益生菌方法的潜力。
Veillonella and Lactobacillus species are key regulators of a healthy gut environment through metabolic cross-feeding, influencing lactic acid and short-chain fatty acid (SCFA) levels, which are crucial for gut health. This study aims to investigate how
Veillonella ratti (V. ratti) and Lactobacillus acidophilus (LA) interact with each other and alleviate dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in a mouse model. We assess their metabolic interactions regarding carbon sources through co-culturing in a modified medium. In the in vitro experiments, V. ratti and LA were inoculated in mono-cultures and co-culture, and viable cell counts, OD600, pH, lactic acid, glucose and SCFAs were measured. For the in vivo experiment, 60 C57BL/6 mice were randomly divided into five groups and administered V. ratti and LA alone or in combination via oral gavage (1 × 109 CFU mL-1 per day per mouse) for 14 days. On the seventh day, 2.5% DSS was added to the drinking water to induce colitis. The effects of these probiotics on UC were evaluated by assessing intestinal barrier integrity and intestinal inflammation in the gut microenvironment. In vitro results demonstrated that co-culturing V. ratti with LA significantly increased viable cell numbers, lactic acid production, and SCFA production, while reducing pH and glucose levels in the medium. In vivo findings revealed that intervention with V. ratti, particularly in combination with LA, alleviated symptoms, including weight loss, colon shortening, and tissue damage. These probiotics mitigated intestinal inflammation by down-regulating pro-inflammatory molecules, such as IL-6, IL-1β, IL-γ, iNOS, and IFN-γ, as well as oxidative stress markers, including MDA and MPO. Concurrently, they upregulated the activity of anti-inflammatory enzymes, namely, SOD and GSH, and promoted the production of SCFAs. The combined intervention of V. ratti and LA significantly increased acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and total SCFAs in cecal contents. Furthermore, the intervention of V. ratti and LA increased the abundance of beneficial bacteria, such as Akkermansia, while reducing the abundance of harmful bacteria, such as Escherichia-Shigella and Desulfovibrio, thereby mitigating excessive inflammation. These findings highlight the enhanced therapeutic effects resulting from the interactions between V. ratti and LA, demonstrating the potential of this combined probiotic approach.